Halozyme Therapeutics (NASDAQ:HALO) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Halozyme Therapeutics (NASDAQ:HALO) released its earnings results on Thursday. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.09, FiscalAI reports. The firm had revenue of $492.97 million for the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm’s revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.72 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported record third-quarter revenue of $493 million, up 39% year over year, including record royalty revenue of $341 million, up 44%. It raised 2026 revenue, royalty, adjusted EBITDA and non-GAAP EPS guidance, citing continued royalty growth.
• Growth is broadening across the commercial portfolio: established products DARZALEX, VYVGART Hytrulo and PHESGO continued to grow, while newer launches OCREVUS ZUNOVO, OPDIVO Qvantig and RYBREVANT FASPRO added to royalties. Halozyme highlighted further conversion potential for the newer products, though adoption and sales projections are based on partner commentary.
• ENHANZE partners added four target nominations, and Halozyme had 12 programs in clinical development, with a 13th expected by year-end. The company also expects the first two Hypercon partner programs to enter Phase I in the first half of 2027; Aerocon remains earlier-stage, with clinical entry targeted for the second half of 2028.
• A Dutch court found Merck’s KEYTRUDA QLEX infringed Halozyme’s EP622 patent and barred specified Merck entities from infringing in several European markets; Halozyme said the ruling supports its position in Europe. The company noted that U.S. patent proceedings have produced adverse initial rulings and that its expected appeal process could continue until 2028.
• Halozyme ended the quarter with $1.08 billion in cash and marketable securities, $3.3 billion in long-term debt and 2.4x net leverage after completing a $1.5 billion convertible-note offering. It also repurchased $400 million of shares in 2026 and said it remains focused on investing in its platforms and deleveraging.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $7.38 during midday trading on Thursday, reaching $122.96. 2,881,580 shares of the company’s stock traded hands, compared to its average volume of 2,144,628. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The company has a market cap of $13.96 billion, a P/E ratio of 26.44, a PEG ratio of 0.49 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a fifty day simple moving average of $115.26 and a two-hundred day simple moving average of $84.57.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $83,995,132. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research reports. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Tuesday. HC Wainwright lifted their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $99.64.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 39% year over year to a record $493 million, while royalty revenue climbed 44% to $341 million. Adjusted EPS of $2.39 also exceeded analysts’ estimates of about $2.30. Halozyme Q3 2026 results and guidance
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting revenue of $1.86 billion–$1.925 billion, royalty revenue of $1.235 billion–$1.255 billion, and adjusted EPS of $8.75–$9.05. It also reported expanded ENHANZE collaborations with three existing partners and three programs entering Phase 1 development. Halozyme Q3 2026 results and guidance
• Negative Sentiment: HALO shares fell despite the earnings beat and higher guidance. The market reaction suggests investors may have been looking for stronger results or may have taken profits, though the cited reports do not identify a specific cause. Halozyme surprises with Q3 sales but stock drops

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.